CL2021002847A1 - Combination therapies comprising apremilast and tyk2 inhibitors - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors

Info

Publication number
CL2021002847A1
CL2021002847A1 CL2021002847A CL2021002847A CL2021002847A1 CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1 CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1
Authority
CL
Chile
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
CL2021002847A
Other languages
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021002847A1 publication Critical patent/CL2021002847A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.Provided herein are methods of treating diseases and disorders responsive to PDE4 inhibition comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.

CL2021002847A 2019-04-30 2021-10-29 Combination therapies comprising apremilast and tyk2 inhibitors CL2021002847A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
CL2021002847A1 true CL2021002847A1 (en) 2022-07-22

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002847A CL2021002847A1 (en) 2019-04-30 2021-10-29 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015614A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
JP6022548B2 (en) * 2011-04-28 2016-11-09 セルジーン コーポレイション Methods and compositions for using PDE4 inhibitors in the treatment and management of autoimmune and inflammatory diseases
EP3756650A1 (en) 2011-12-27 2020-12-30 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
CN104159891B (en) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 Pyridazine amide compound and they are as the purposes of SYK inhibitor
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
ES2702148T3 (en) * 2012-11-08 2019-02-27 Bristol Myers Squibb Co Amide substituted heterocyclic compounds useful as modulators of il-12, il-23 and / or ifn-alpha
EP2917186B1 (en) * 2012-11-08 2017-10-18 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn
CN105050624A (en) * 2013-03-14 2015-11-11 细胞基因公司 Treatment of psoriatic arthritis using apremilast
US20160159773A1 (en) 2013-07-30 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6239118B2 (en) 2013-09-03 2017-11-29 サリウム リミテッド Pharmaceutical compounds
AR094537A1 (en) 2013-11-07 2015-08-12 Bristol Myers Squibb Co PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CN106661039B (en) 2014-02-28 2019-09-13 林伯士拉克许米公司 2 (TYK2) inhibitor of tyrosine protein matter kinases and its purposes
ES2749433T3 (en) 2014-06-23 2020-03-20 Celgene Corp Apremilast for the treatment of liver disease or abnormal liver function
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
JP6802263B2 (en) 2015-09-02 2020-12-16 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitor and its use
NZ744349A (en) 2016-02-24 2023-06-30 Pfizer Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CN110036015B (en) 2016-10-07 2022-07-19 百时美施贵宝公司 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha response
EP3848370A3 (en) 2016-10-14 2021-09-15 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN110300590A (en) 2016-10-21 2019-10-01 林伯士拉克许米公司 TYK2 inhibitor and application thereof
MA46620A (en) 2016-10-28 2021-05-26 Bristol Myers Squibb Co USEFUL HETEROBICYCLIC COMPOUNDS AS MODULATORS OF RESPONSES TO IL-12, IL-23 AND / OR IFN ALPHA
CN110191887B (en) 2016-11-17 2022-02-18 百时美施贵宝公司 Imidazopyridazine modulators of IL-12, IL-23 and/or IFN-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TW202321243A (en) * 2017-03-08 2023-06-01 美商林伯士拉克許米公司 Methods for production of tyk2 inhibitors
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
KR20220002488A (en) 2022-01-06
CN114269336A (en) 2022-04-01
EP3962475A1 (en) 2022-03-09
WO2020222773A1 (en) 2020-11-05
CA3138473A1 (en) 2020-11-05
SG11202112018YA (en) 2021-11-29
WO2020223431A1 (en) 2020-11-05
BR112021021826A2 (en) 2022-01-04
BR112021021826A8 (en) 2022-06-21
JP7453251B2 (en) 2024-03-19
IL287670A (en) 2021-12-01
EP3962476A1 (en) 2022-03-09
CN114206333A (en) 2022-03-18
JP2022537877A (en) 2022-08-31
AU2020266143A1 (en) 2021-12-02
MX2021013317A (en) 2022-01-18
MX2021013318A (en) 2022-01-31
CO2021015622A2 (en) 2022-02-28
CO2021015614A2 (en) 2021-12-10
KR20220002489A (en) 2022-01-06
BR112021021809A2 (en) 2022-01-04
IL287665A (en) 2022-07-01
CA3138686A1 (en) 2020-11-05
AU2019443366A1 (en) 2021-12-02
SG11202112043PA (en) 2021-11-29
MA55799A (en) 2022-03-09
JP2022537878A (en) 2022-08-31

Similar Documents

Publication Publication Date Title
CO2021015622A2 (en) Combination therapies comprising apremilast and tyk2 inhibitors
BR112021017495A2 (en) Pyrazine derivative and its application in shp2 inhibition
CL2021000382A1 (en) Novel sulfonamidaurea compounds
MX2018005600A (en) Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor.
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
BR112018001640A2 (en) combination of pd-1 antagonist with an egfr inhibitor
MX2022007376A (en) Fluoroalkyl-oxadiazoles and uses thereof.
BR112017013022A2 (en) methods for treating acute inflammatory and / or autoimmune disease in a mammal in need thereof where corticosteroid therapy is used as first or second line therapy and / or for treating an inflammatory and / or autoimmune disease in a mammal in need where corticosteroid therapy is required. Corticosteroid therapy is used as first or second line maintenance therapy and / or to eliminate or reduce therapeutic dose of corticosteroids used to treat an inflammatory and / or autoimmune disease in a mammal in need thereof, where corticosteroid therapy is used as first or second-line chronic maintenance therapy and / or treatment of an autoimmune and / or inflammatory disease in a mammal in need thereof
BR112015010477A2 (en) A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
BR112015026021A2 (en) combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201790907A1 (en) NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS
ECSP22044525A (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
BR112021018739A8 (en) Compositions and methods for treating diseases or disorders associated with kras
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
BR112023000687A2 (en) METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR THE TREATMENT OF CANCER
BR112023015210A2 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
BR112022011892A2 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
CL2022001006A1 (en) tim-3 inhibitors and their uses
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
EA201990508A1 (en) ACTIVITY INHIBITION Olig2
AR116024A1 (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
BR112022008580A2 (en) METHODS TO TREAT DEPRESSIVE DISORDERS